Calendario›CPIX›Ifetroban · DMD

Ifetroban · DMD

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Ensayo de CUMBERLAND PHARMACEUTICALS INC en Duchenne Muscular Dystrophy Cardiomyopathy · Cardiomyopathy, Dilated (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

46

previstos

Centros

10

Fin del objetivo primario

mar 2024

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en oct 2020.

Qué mide

Incidence of Treatment-Emergent Adverse Events (del registro, en inglés) (del inicio a los 12 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroDuchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD. Funding Source - FDA OOPD

Más ensayos de CPIX

Todos los de CPIX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03340675), actualizada en mar 2026.